Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Lunches in UK early years education and care settings: cross-sectional analysis of food processing, provision and intake.

Research square·2026
Same author

Pharmacokinetic, Safety, and Immunogenicity Similarity of High- and Low-Concentration Formulations of Adalimumab Biosimilar ABP 501, Adalimumab-Atto.

Pharmacology research & perspectives·2026
Same author

From 3-Tier to adaptive immunogenicity testing strategies: recommendations from the European Bioanalysis Forum.

Bioanalysis·2026
Same author

Progress and promise of pharmacodynamic biomarkers: novel strategies and assay considerations in drug development.

Bioanalysis·2026
Same author

Proceedings of the 2024 FDA-CRCG Workshop: Scientific and Regulatory Considerations for Assessment of Immunogenicity Risk for Generic Peptide and Oligonucleotide Drug Products.

The AAPS journal·2026
Same author

2025 White Paper on Recent Issues in Bioanalysis: Biomarkers Calibrators & Stability; Evaluation of NULISA; Neurofilament & Autoantibody Biomarker Assays; Removing IgM Interference; ELISpot & FluoroSpot Best Practices; Modular HD Cytometry; Single-cell Analysis Imaging Cytometry (PART 2A - Recommendations on Biomarkers Discovery, Development, Validation & Regulatory Approval, Ligand-Binding Assays (LBA) and Cell-Based Assays (CBA) PART 2B - Regulatory Agencies' Input on Biomarkers, IVD/CDx and Biomarker Assay Validation (BAV)).

Bioanalysis·2026
Same journal

Updated Recommendations for the Bioanalysis of Antibody-Drug Conjugates (ADC) from the ADC working group of the AAPS Bioanalytical Community.

The AAPS journal·2026
Same journal

In vivo Predictive Dissolution Test Using Biorelevant Bicarbonate Buffer for High-dose Free Acid Drug.

The AAPS journal·2026
Same journal

Whole-Body Pharmacokinetics of Ionizable Lipid, mRNA, and the Expressed Antibody following Intravenous Administration of mRNA-Loaded Lipid Nanoparticles.

The AAPS journal·2026
Same journal

Simple Hydrodynamic Molecular Weight Model for Rapid Assessment of Therapeutic Protein Oligomerization States in Formulation.

The AAPS journal·2026
Same journal

Guiding the Molnupiravir Tablet Formulation Using Physiologically Based Biopharmaceutics Modeling and Successfully Establishing Dissolution Safe Space.

The AAPS journal·2026
Same journal

Correction: Nanotechnology-enhanced Natural Products for Cancer Chemoprevention: Molecular Mechanisms and Clinical Translation.

The AAPS journal·2026
See all related articles

Related Experiment Video

Updated: Jun 21, 2025

Detection of Antibodies That Neutralize the Cellular Uptake of Enzyme Replacement Therapies with a Cell-based Assay
07:52

Detection of Antibodies That Neutralize the Cellular Uptake of Enzyme Replacement Therapies with a Cell-based Assay

Published on: September 10, 2018

8.8K

Neutralizing Antibody Sample Testing and Report Harmonization.

Darshana Jani1, Michele Gunsior2, Robin Marsden3

  • 1Bioanalytical and Molecular Assays, Moderna, 325 Binney Street, Cambridge, Massachusetts, USA. darshana.jani@modernatx.com.

The AAPS Journal
|July 11, 2024
PubMed
Summary
This summary is machine-generated.

Standardizing the reporting of neutralizing antibody (NAb) assay results is crucial for protein therapeutics. This work provides harmonized recommendations and a template for bioanalytical reports to improve communication and regulatory review.

Keywords:
bioanalytical reportimmunogenicitymulti-functional therapeuticsneutralizing antibodytemplate

More Related Videos

A Rapid, Multiplex Dual Reporter IgG and IgM SARS-CoV-2 Neutralization Assay for a Multiplexed Bead-Based Flow Analysis System
07:08

A Rapid, Multiplex Dual Reporter IgG and IgM SARS-CoV-2 Neutralization Assay for a Multiplexed Bead-Based Flow Analysis System

Published on: April 6, 2021

5.0K
Author Spotlight: Expanding the Scope of Multiplex Immunoassays for Lyme Borreliosis Diagnostics and Pathogen Research
05:25

Author Spotlight: Expanding the Scope of Multiplex Immunoassays for Lyme Borreliosis Diagnostics and Pathogen Research

Published on: July 14, 2023

1.4K

Related Experiment Videos

Last Updated: Jun 21, 2025

Detection of Antibodies That Neutralize the Cellular Uptake of Enzyme Replacement Therapies with a Cell-based Assay
07:52

Detection of Antibodies That Neutralize the Cellular Uptake of Enzyme Replacement Therapies with a Cell-based Assay

Published on: September 10, 2018

8.8K
A Rapid, Multiplex Dual Reporter IgG and IgM SARS-CoV-2 Neutralization Assay for a Multiplexed Bead-Based Flow Analysis System
07:08

A Rapid, Multiplex Dual Reporter IgG and IgM SARS-CoV-2 Neutralization Assay for a Multiplexed Bead-Based Flow Analysis System

Published on: April 6, 2021

5.0K
Author Spotlight: Expanding the Scope of Multiplex Immunoassays for Lyme Borreliosis Diagnostics and Pathogen Research
05:25

Author Spotlight: Expanding the Scope of Multiplex Immunoassays for Lyme Borreliosis Diagnostics and Pathogen Research

Published on: July 14, 2023

1.4K

Area of Science:

  • Biotechnology
  • Pharmacology
  • Immunology

Background:

  • Immunogenicity testing is vital for protein therapeutics.
  • Neutralizing antibody (NAb) assays detect anti-drug antibody (ADA) responses.
  • Standardized reporting enhances communication and regulatory review.

Purpose of the Study:

  • To harmonize reporting recommendations for NAb assays.
  • To provide a template for bioanalytical report (BAR) submissions.
  • To address reporting gaps in immunogenicity data.

Main Methods:

  • Convened a cross-industry group of NAb assay experts.
  • Developed harmonized reporting recommendations.
  • Created an editable BAR submission template.

Main Results:

  • Established a standardized structure for NAb assay reports.
  • Included essential elements: method, reagents, equipment, data analysis, samples, and results.
  • Facilitated consistent documentation for agency filings.

Conclusions:

  • Harmonized NAb assay reporting improves clarity and efficiency.
  • The provided template aids in consistent BAR submissions.
  • Standardization supports better understanding of immune responses to biologics.